Vaccines licensed and in clinical trials for the prevention of dengue

References

• Tatem AJ, Hay SI, Rogers DJ. Global traffic and disease vector dispersal. Proc Natl Acad Sci U S A 2006; 103:6242-7; PMID:16606847; http://dx.doi.org/10.1073/pnas.0508391103
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global strategy for dengue prevention and control 2012
   Google Scholar
• Tapia-Conyer R, Betancourt-Cravioto M, Mendez-Galvan J. Dengue: an escalating public health problem in Latin America. Paediatr Int Child Health 2012; 32 Suppl 1:14-7; PMID:22668444; http://dx.doi.org/10.1179/2046904712Z.00000000046
   PubMed Web of Science ®Google Scholar
• Dantes HG, Farfan-Ale JA, Sarti E. Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis. PLoS Negl Trop Dis 2014; 8:e3158; PMID:25375162; http://dx.doi.org/10.1371/journal.pntd.0003158
   PubMed Web of Science ®Google Scholar
• Bravo L, Roque VG, Brett J, Dizon R, L'Azou M. Epidemiology of dengue disease in the Philippines (2000-2011): a systematic literature review. PLoS Negl Trop Dis 2014; 8:e3027; PMID:25375119; http://dx.doi.org/10.1371/journal.pntd.0003027
   PubMed Web of Science ®Google Scholar
• Mohd-Zaki AH, Brett J, Ismail E, L'Azou M. Epidemiology of dengue disease in Malaysia (2000-2012): a systematic literature review. PLoS Negl Trop Dis 2014; 8:e3159; PMID:25375211; http://dx.doi.org/10.1371/journal.pntd.0003159
   PubMed Web of Science ®Google Scholar
• Limkittikul K, Brett J, L'Azou M. Epidemiological trends of dengue disease in Thailand (2000-2011): a systematic literature review. PLoS Negl Trop Dis 2014; 8:e3241; PMID:25375766; http://dx.doi.org/10.1371/journal.pntd.0003241
   PubMed Web of Science ®Google Scholar
• Teixeira MG, Siqueira JB, Jr, Ferreira GL, Bricks L, Joint G. Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis. PLoS Negl Trop Dis 2013; 7:e2520; PMID:24386496; http://dx.doi.org/10.1371/journal.pntd.0002520
   PubMed Web of Science ®Google Scholar
• Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113-23; PMID:25365753; http://dx.doi.org/10.1056/NEJMoa1411037
   PubMed Web of Science ®Google Scholar
• Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7; PMID:23563266; http://dx.doi.org/10.1038/nature12060
   PubMed Web of Science ®Google Scholar
• Ratnam I, Black J, Leder K, Biggs BA, Matchett E, Padiglione A, Woolley I, Panagiotidis T, Gherardin T, Pollissard L, et al. Incidence and seroprevalence of dengue virus infections in Australian travellers to Asia. Eur J Clin Microbiol Infect Dis 2012; 31:1203-10; PMID:21983919; http://dx.doi.org/10.1007/s10096-011-1429-1
   PubMed Web of Science ®Google Scholar
• Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg F, Keystone JS, Pandey P, Cetron MS. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354:119-30; PMID:16407507; http://dx.doi.org/10.1056/NEJMoa051331
   PubMed Web of Science ®Google Scholar
• Leder K, Mutsch M, Schlagenhauf P, Luxemburger C, Torresi J. Seroepidemiology of dengue in travellers: A paired sera analysis. Travel Med Infect Dis 2013; 11:210-3; PMID:23890678; http://dx.doi.org/10.1016/j.tmaid.2013.06.008
   PubMed Web of Science ®Google Scholar
• Gomez-Dantes H, Willoquet JR. Dengue in the Americas: challenges for prevention and control. Cad Saude Publica 2009; 25 Suppl 1:S19-31; PMID:19287863; http://dx.doi.org/10.1590/S0102-311X2009001300003
   PubMed Web of Science ®Google Scholar
• Flipse J, Smit JM. The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response. PLoS Negl Trop Dis 2015; 9:e0003749; PMID:26065421; http://dx.doi.org/10.1371/journal.pntd.0003749
   PubMed Web of Science ®Google Scholar
• Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011; 11:532-43; PMID:21760609; http://dx.doi.org/10.1038/nri3014
   PubMed Web of Science ®Google Scholar
• Screaton G, Mongkolsapaya J, Yacoub S, Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol 2015; 15:745-59; PMID:26603900; http://dx.doi.org/10.1038/nri3916
   PubMed Web of Science ®Google Scholar
• Green AM, Beatty PR, Hadjilaou A, Harris E. Innate immunity to dengue virus infection and subversion of antiviral responses. J Mol Biol 2014; 426:1148-60; PMID:24316047; http://dx.doi.org/10.1016/j.jmb.2013.11.023
   PubMed Web of Science ®Google Scholar
• Wu MF, Chen ST, Yang AH, Lin WW, Lin YL, Chen NJ, Tsai IS, Li L, Hsieh SL. CLEC5A is critical for dengue virus-induced inflammasome activation in human macrophages. Blood 2013; 121:95-106; PMID:23152543; http://dx.doi.org/10.1182/blood-2012-05-430090
   PubMed Web of Science ®Google Scholar
• Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, Waiyaiya E, Tran HB, Cowper AE, Chotiyarnwong P, et al. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol 2011; 85:410-21; PMID:20980526; http://dx.doi.org/10.1128/JVI.01826-10
   PubMed Web of Science ®Google Scholar
• Malavige GN, Huang LC, Salimi M, Gomes L, Jayaratne SD, Ogg GS. Cellular and cytokine correlates of severe dengue infection. PLoS One 2012; 7:e50387; PMID:23209731; http://dx.doi.org/10.1371/journal.pone.0050387
   PubMed Web of Science ®Google Scholar
• Pandey N, Jain A, Garg RK, Kumar R, Agrawal OP, Lakshmana Rao PV. Serum levels of IL-8, IFNgamma, IL-10, and TGF beta and their gene expression levels in severe and non-severe cases of dengue virus infection. Arch Virol 2015; 160:1463-75; PMID:25860648; http://dx.doi.org/10.1007/s00705-015-2410-6
   PubMed Web of Science ®Google Scholar
• Schmid MA, Diamond MS, Harris E. Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity. Front Immunol 2014; 5:647; PMID:25566258; http://dx.doi.org/10.3389/fimmu.2014.00647
   PubMed Web of Science ®Google Scholar
• Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW, Teo GH, Gan VC, Lye DC, Leo YS, et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol 2013; 87:2693-706; PMID:23255803; http://dx.doi.org/10.1128/JVI.02675-12
   PubMed Web of Science ®Google Scholar
• Rothman AL, Currier JR, Friberg HL, Mathew A. Analysis of cell-mediated immune responses in support of dengue vaccine development efforts. Vaccine 2015; 33:7083-90; PMID:26458801; http://dx.doi.org/10.1016/j.vaccine.2015.09.104
   PubMed Web of Science ®Google Scholar
• Dowd KA, Pierson TC. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 2011; 411:306-15; PMID:21255816; http://dx.doi.org/10.1016/j.virol.2010.12.020
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, Jumnainsong A, Edwards C, Quyen NT, Duangchinda T, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 2015; 16:170-7; PMID:25501631; http://dx.doi.org/10.1038/ni.3058
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Ibarra KD, Ng TS, Smith SA, Tan JL, Lim XN, Ooi JS, Kostyuchenko VA, Wang J, de Silva AM, et al. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 2015; 349:88-91; PMID:26138979; http://dx.doi.org/10.1126/science.aaa8651
   PubMed Web of Science ®Google Scholar
• Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio 2013; 4:e00873-13; PMID:24255124
   PubMed Web of Science ®Google Scholar
• de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 2012; 109:7439-44; PMID:22499787; http://dx.doi.org/10.1073/pnas.1200566109
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med 2014; 6:358-71; PMID:24421336
   PubMed Web of Science ®Google Scholar
• de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Tsai WY, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 2011; 5:e1188; PMID:21713020; http://dx.doi.org/10.1371/journal.pntd.0001188
   PubMed Web of Science ®Google Scholar
• Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009; 392:103-13; PMID:19631955; http://dx.doi.org/10.1016/j.virol.2009.06.037
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Ng TS, Kostyuchenko VA, Lee J, Lee S, Wang J, Lok SM. Structural changes in dengue virus when exposed to a temperature of 37 °C. J Virol 2013; 87:7585-92; PMID:23637405; http://dx.doi.org/10.1128/JVI.00757-13
   PubMed Web of Science ®Google Scholar
• Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 2008; 15:312-7; PMID:18264114; http://dx.doi.org/10.1038/nsmb.1382
   PubMed Web of Science ®Google Scholar
• Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, Johnson S, Pierson TC, Diamond MS, Fremont DH. Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog 2012; 8:e1002930; PMID:23055922; http://dx.doi.org/10.1371/journal.ppat.1002930
   PubMed Web of Science ®Google Scholar
• Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 2010; 84:9227-39; PMID:20592088; http://dx.doi.org/10.1128/JVI.01087-10
   PubMed Web of Science ®Google Scholar
• Zust R, Toh YX, Valdes I, Cerny D, Heinrich J, Hermida L, Marcos E, Guillén G, Kalinke U, Shi PY, et al. Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines. J Virol 2014; 88:7276-85; PMID:24741106; http://dx.doi.org/10.1128/JVI.03827-13
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A 2013; 110:E2046-53; PMID:23580623; http://dx.doi.org/10.1073/pnas.1305227110
   PubMed Web of Science ®Google Scholar
• Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog 2013; 9:e1003723; PMID:24204271; http://dx.doi.org/10.1371/journal.ppat.1003723
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Bangs DJ, Sidney J, Kolla RV, De Silva AD, de Silva AM, Crotty S, Peters B, Sette A. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc Natl Acad Sci U S A 2015; 112:E4256-63; PMID:26195744; http://dx.doi.org/10.1073/pnas.1505956112
   PubMed Web of Science ®Google Scholar
• Schmitt N, Bentebibel SE, Ueno H. Phenotype and functions of memory Tfh cells in human blood. Trends Immunol 2014; 35:436-42; PMID:24998903; http://dx.doi.org/10.1016/j.it.2014.06.002
   PubMed Web of Science ®Google Scholar
• Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, Volpini G, Fragapane E, Tavarini S, Finco O, Rappuoli R, et al. Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci U S A 2013; 110:14330-5; PMID:23940329; http://dx.doi.org/10.1073/pnas.1311998110
   PubMed Web of Science ®Google Scholar
• Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, Flano E, Mejias A, Albrecht RA, Blankenship D, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 2013; 5:176ra32; PMID:23486778; http://dx.doi.org/10.1126/scitranslmed.3005191
   PubMed Web of Science ®Google Scholar
• Li Y, Ma S, Tang L, Wang W, Huang X, Lai Q, Zhang M, Sun J, Li CK, Abbott WG, et al. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection. Hepatology 2013; 58:1277-86; PMID:23703545; http://dx.doi.org/10.1002/hep.26489
   PubMed Web of Science ®Google Scholar
• Spaan M, Kreefft K, de Graav GN, Brouwer WP, de Knegt RJ, Ten Kate FJ, Baan CC, Vanwolleghem T, Janssen HL, Boonstra A. CD4(+)CXCR5(+) T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses. J Hepatol 2015; 62:303-10; PMID:25281860; http://dx.doi.org/10.1016/j.jhep.2014.09.024
   PubMed Web of Science ®Google Scholar
• Guy B, Saville M, Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010; 6; PMID:20861669; http://dx.doi.org/10.4161/hv.6.9.12739
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006; 2:60-7; PMID:17012873; http://dx.doi.org/10.4161/hv.2.2.2555
   PubMed Web of Science ®Google Scholar
• Guy B. Immunogenicity of sanofi pasteur tetravalent dengue vaccine. J Clin Virol 2009; 46:S16-S9; PMID:19800561; http://dx.doi.org/10.1016/S1386-6532(09)70290-2
   PubMed Web of Science ®Google Scholar
• Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29:7229-41; PMID:21745521; http://dx.doi.org/10.1016/j.vaccine.2011.06.094
   PubMed Web of Science ®Google Scholar
• Guy B, Briand O, Lang J, Saville M, Jackson N. Development of the Sanofi Pastuer tetravalent dengue vaccine: one more step forward. Vaccine 2015; 33:7100-11; PMID:26475445; http://dx.doi.org/10.1016/j.vaccine.2015.09.108
   PubMed Web of Science ®Google Scholar
• Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010; 28:632-49; PMID:19808029; http://dx.doi.org/10.1016/j.vaccine.2009.09.098
   PubMed Web of Science ®Google Scholar
• Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 2016; 14:45-54; PMID:26639777; http://dx.doi.org/10.1038/nrmicro.2015.2
   PubMed Web of Science ®Google Scholar
• Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, Chambonneau L, Morrisson DN, Shaw D, Qiao M, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008; 26:5712-21; PMID:18762226; http://dx.doi.org/10.1016/j.vaccine.2008.08.019
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet (London, England) 2012; 380:1559-67; PMID:22975340; http://dx.doi.org/10.1016/S0140-6736(12)61428-7
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet (London, England) 2014; 384:1358-65; PMID:25018116; http://dx.doi.org/10.1016/S0140-6736(14)61060-6
   PubMed Web of Science ®Google Scholar
• Torresi J, Heron LG, Qiao M, Marjason J, Chambonneau L, Bouckenooghe A, Boaz M, van der Vliet D, Wallace D, Hutagalung Y, et al. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. Vaccine 2015; 33:5127-34; PMID:26279339; http://dx.doi.org/10.1016/j.vaccine.2015.08.008
   PubMed Web of Science ®Google Scholar
• Wren LH, Chung AW, Isitman G, Kelleher AD, Parsons MS, Amin J, Cooper DA. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 2013; 138:116-23; PMID:23173935; http://dx.doi.org/10.1111/imm.12016
   PubMed Web of Science ®Google Scholar
• Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, Winnall WR, Stratov I, Brooks AG, Reading PC, et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 2013; 190:1837-48; PMID:23319732; http://dx.doi.org/10.4049/jimmunol.1201574
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015; 373:1195-206; PMID:26214039; http://dx.doi.org/10.1056/NEJMoa1506223
   PubMed Web of Science ®Google Scholar
• Gailhardou S, Skipetrova A, Dayan GH, Jezorwski J, Saville M, Van der Vliet D, Wartel TA. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials. PLoS Negl Trop Dis 2016; 10:e0004821; PMID:27414655; http://dx.doi.org/10.1371/journal.pntd.0004821
   PubMed Web of Science ®Google Scholar
• Olivera-Botello G, Coudeville L, Fanouillere K, Guy B, Chambonneau L, Noriega F, Jackson N. Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue infections in healthy children and adolescents aged 2–16 years in Asia and Latin America. J Infect Dis 2016; 214(7):994-1000; PMID:27418050
   PubMed Web of Science ®Google Scholar
• Osorio JE, Partidos CD, Wallace D, Stinchcomb DT. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Vaccine 2015; 33:7112-20; PMID:26585500; http://dx.doi.org/10.1016/j.vaccine.2015.11.022
   PubMed Web of Science ®Google Scholar
• Huang CY, Kinney RM, Livengood JA, Bolling B, Arguello JJ, Luy BE, Silengo SJ, Boroughs KL, Stovall JL, Kalanidhi AP, et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis 2013; 7:e2243; PMID:23738026; http://dx.doi.org/10.1371/journal.pntd.0002243
   PubMed Web of Science ®Google Scholar
• Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011; 29:7251-60; PMID:21777638; http://dx.doi.org/10.1016/j.vaccine.2011.07.020
   PubMed Web of Science ®Google Scholar
• Brewoo JN, Kinney RM, Powell TD, Arguello JJ, Silengo SJ, Partidos CD, Huang CY, Stinchcomb DT, Osorio JE. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine 2012; 30:1513-20; PMID:22178727; http://dx.doi.org/10.1016/j.vaccine.2011.11.072
   PubMed Web of Science ®Google Scholar
• Henriques HR, Rampazo EV, Goncalves AJ, Vicentin EC, Amorim JH, Panatieri RH, Amorim KN, Yamamoto MM, Ferreira LC, Alves AM, et al. Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge. PLoS Negl Trop Dis 2013; 7:e2330; PMID:23875054; http://dx.doi.org/10.1371/journal.pntd.0002330
   PubMed Web of Science ®Google Scholar
• Osorio JE, Brewoo JN, Silengo SJ, Arguello J, Moldovan IR, Tary-Lehmann M, Powell TD, Livengood JA, Kinney RM, Huang CY, et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am J Trop Med Hyg 2011; 84:978-87; PMID:21633037; http://dx.doi.org/10.4269/ajtmh.2011.10-0592
   PubMed Web of Science ®Google Scholar
• Fuchs J, Chu H, O'Day P, Pyles R, Bourne N, Das SC, Milligan GN, Barrett AD, Partidos CD, Osorio JE. Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice. Vaccine 2014; 32:6537-43; PMID:25239488; http://dx.doi.org/10.1016/j.vaccine.2014.08.087
   PubMed Web of Science ®Google Scholar
• Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA, Silengo S, Scott J, Boroughs KL, Stovall JL, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis 2014; 14:830-8; PMID:25087476; http://dx.doi.org/10.1016/S1473-3099(14)70811-4
   PubMed Web of Science ®Google Scholar
• George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE, Haller AA, Osorio JE, Eggemeyer LM, Irby-Moore S, et al. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial. J Infect Dis 2015; 212:1032-41; PMID:25791116; http://dx.doi.org/10.1093/infdis/jiv179
   PubMed Web of Science ®Google Scholar
• Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, Sariol CA, Shek LP, Simasathien S, Smith MK, Velez ID, et al. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. J Infect Dis 2016; 213:1562-72; PMID:26704612; http://dx.doi.org/10.1093/infdis/jiv762
   PubMed Web of Science ®Google Scholar
• Precioso AR, Palacios R, Thome B, Mondini G, Braga P, Kalil J. Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine. Vaccine 2015; 33:7121-5; PMID:26458796; http://dx.doi.org/10.1016/j.vaccine.2015.09.105
   PubMed Web of Science ®Google Scholar
• Lindow JC, Durbin AP, Whitehead SS, K.K. P, Carmolli MP, Kirkpatrick BD. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads toserotype-specific immunologic and virologic profiles. Vaccine 2013; 31:3347-52; PMID:23735680; http://dx.doi.org/10.1016/j.vaccine.2013.05.075
   PubMed Web of Science ®Google Scholar
• Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, et al. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. J Infect Dis 2015; ;212(5):702-10; PMID:25801652
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, de Silva AD, Lindow JC, Diehl SA, Whitehead S, et al. The Human CD8 T Cell Responses Induced by a Live Attenuated Tetravalent Dengue Vaccine Are Directed against Highly Conserved Epitopes. J Virol 2015; 89:120-8; PMID:25320311; http://dx.doi.org/10.1128/JVI.02129-14
   PubMed Web of Science ®Google Scholar
• Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wanionek K, Thumar B, Blaney JE, Murphy BR, Schmidt AC. A single dose of the DENV-1 candidate vaccine rDEN1Delta30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. PLoS Negl Trop Dis 2011; 5:e1267; PMID:21829748; http://dx.doi.org/10.1371/journal.pntd.0001267
   PubMed Web of Science ®Google Scholar
• Durbin AP, McArthur JH, Marron JA, Blaney JE, Thumar B, Wanionek K, Murphy BR, Whitehead SS. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2006; 2:255-60; PMID:17106267; http://dx.doi.org/10.4161/hv.2.6.3494
   PubMed Web of Science ®Google Scholar
• Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE, Jr, Thumar B, Murphy BR, Karron RA. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005; 191:710-8; PMID:15688284; http://dx.doi.org/10.1086/427780
   PubMed Web of Science ®Google Scholar
• Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 2013; 207:957-65; PMID:23329850; http://dx.doi.org/10.1093/infdis/jis936
   PubMed Web of Science ®Google Scholar
• Manoff SB, George SL, Bett AJ, Yelmene ML, Dhanasekaran G, Eggemeyer L, Sausser ML, Dubey SA, Casimiro DR, Clements DE, et al. Preclinical and clinical development of a dengue recombinant subunit vaccine. Vaccine 2015; 33:7126-34; PMID:26458804; http://dx.doi.org/10.1016/j.vaccine.2015.09.101
   PubMed Web of Science ®Google Scholar
• Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010; 28:2705-15; PMID:20097152; http://dx.doi.org/10.1016/j.vaccine.2010.01.022
   PubMed Web of Science ®Google Scholar
• Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011; 29:7267-75; PMID:21777637; http://dx.doi.org/10.1016/j.vaccine.2011.07.021
   PubMed Web of Science ®Google Scholar
• Govindarajan D, Meschino S, Guan L, Clements DE, ter Meulen JH, Casimiro DR, Coller BA, Bett AJ. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates. Vaccine 2015; 33:4105-16; PMID:26144900; http://dx.doi.org/10.1016/j.vaccine.2015.06.067
   PubMed Web of Science ®Google Scholar
• Porter KR, Raviprakash K. Nucleic acid (DNA) immunization as a platform for dengue vaccine development. Vaccine 2015; 33:7135-40; PMID:26458805; http://dx.doi.org/10.1016/j.vaccine.2015.09.102
   PubMed Web of Science ®Google Scholar
• Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M, Wu SJ, Sun P, Kochel T, Raviprakash K, et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011; 29:960-8; PMID:21111785; http://dx.doi.org/10.1016/j.vaccine.2010.11.050
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G, Ewing D, Wu SJ, Bass S, Punnonen J, et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 2006; 353:166-73; PMID:16814355; http://dx.doi.org/10.1016/j.virol.2006.05.005
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Kochel TJ, Ewing D, Simmons M, Phillips I, Hayes CG, Porter KR. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000; 18:2426-34; PMID:10738100; http://dx.doi.org/10.1016/S0264-410X(99)00570-8
   PubMed Web of Science ®Google Scholar
• Kochel T, Wu SJ, Raviprakash K, Hobart P, Hoffman S, Porter K, Hayes C. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997; 15:547-52; PMID:9160523; http://dx.doi.org/10.1016/S0264-410X(97)00215-6
   PubMed Web of Science ®Google Scholar
• Thomas SJ. Developing a dengue vaccine: progress and future challenges. Ann N Y Acad Sci 2014; 1323:140-59; PMID:24689974; http://dx.doi.org/10.1111/nyas.12413
   PubMed Web of Science ®Google Scholar
• Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG, Ferrari M, Teneza-Mora N, Raviprakash K. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine. Vaccine 2012; 30:336-41; PMID:22085548; http://dx.doi.org/10.1016/j.vaccine.2011.10.085
   PubMed Web of Science ®Google Scholar
• Danner R, Chaudhari SN, Rosenberger J, Surls J, Richie TL, Brumeanu TD, Casares S. Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells. PLoS One 2011; 6:e19826; PMID:21611197; http://dx.doi.org/10.1371/journal.pone.0019826
   PubMed Web of Science ®Google Scholar
• Ippolito GC, Hoi KH, Reddy ST, Carroll SM, Ge X, Rogosch T, Zemlin M, Shultz LD, Ellington AD, Vandenberg CL, et al. Antibody repertoires in humanized NOD-scid-IL2Rgamma(null) mice and human B cells reveals human-like diversification and tolerance checkpoints in the mouse. PLoS One 2012; 7:e35497; PMID:22558161; http://dx.doi.org/10.1371/journal.pone.0035497
   PubMed Web of Science ®Google Scholar
• Singh M, Singh P, Gaudray G, Musumeci L, Thielen C, Vaira D, Vandergeeten C, Delacroix L, Van Gulck E, Vanham G, et al. An improved protocol for efficient engraftment in NOD/LTSZ-SCIDIL-2Rgammanull mice allows HIV replication and development of anti-HIV immune responses. PLoS One 2012; 7:e38491; PMID:22675567; http://dx.doi.org/10.1371/journal.pone.0038491
   PubMed Web of Science ®Google Scholar
• Thomas S, Klobuch S, Sommer M, van Ewijk R, Theobald M, Meyer RG, Herr W. Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell-engrafted NOD/SCID/IL-2Rgammac null mice. Exp Hematol 2014; 42:28-38 e1-2; http://dx.doi.org/10.1016/j.exphem.2013.09.013
   PubMed Web of Science ®Google Scholar
• Mota J, Rico-Hesse R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol 2009; 83:8638-45; PMID:19535452; http://dx.doi.org/10.1128/JVI.00581-09
   PubMed Web of Science ®Google Scholar
• Mota J, Rico-Hesse R. Dengue virus tropism in humanized mice recapitulates human dengue fever. PLoS One 2011; 6:e20762; PMID:21695193; http://dx.doi.org/10.1371/journal.pone.0020762
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Smith K, Ramirez A, Woda M, Pazoles P, Shultz LD, Greiner DL, Brehm MA, Mathew A. Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice. Exp Biol Med (Maywood) 2015; 240:67-78; PMID:25125497; http://dx.doi.org/10.1177/1535370214546273
   PubMed Web of Science ®Google Scholar
• Chung YS, Son JK, Choi B, Joo SY, Lee YS, Park JB, Moon H, Kim TJ, Kim SH, Hong S, et al. Co-transplantation of human fetal thymus, bone and CD34(+) cells into young adult immunodeficient NOD/SCID IL2Rgamma(null) mice optimizes humanized mice that mount adaptive antibody responses. Clin Immunol 2015; 157:156-65; PMID:25725428; http://dx.doi.org/10.1016/j.clim.2015.02.005
   PubMed Web of Science ®Google Scholar
• Chung YS, Son JK, Choi B, Park JB, Chang J, Kim SJ. Transplantation of human spleen into immunodeficient NOD/SCID IL2Rgamma(null) mice generates humanized mice that improve functional B cell development. Clin Immunol 2015; 161:308-15; PMID:26360254; http://dx.doi.org/10.1016/j.clim.2015.09.001
   PubMed Web of Science ®Google Scholar